Earnings Call · Q4 FY2021·2022-01-26

Q4 21EPS +2.43%·Rev n/aQ3 21EPS +15.96%·Rev n/aQ2 21EPS +30.67%·Rev n/aQ1 21EPS +10.78%·Rev n/a⚠ consensus missing

VERTEX PHARMACEUTICALS INC / MA VRTX

Michael Partridge — Senior Vice President of Investor Relations

Reshma Kewalramani — Chief Executive Officer and President

Stuart Arbuckle — Chief Operating Officer

Charles Wagner — Chief Financial Officer

+0.7%1d on move date+1.2% vs SPY3d+7.3%5d+11.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VRTX calls or request research access.

More VRTX calls Browse calls Request research access